Group 1 - The core viewpoint of the news is that the market's reaction to the pre-sale performance of Giant Bio during the live broadcast by influencer Li Jiaqi is considered excessive, as the company's promotional strategy has made its products less price-attractive compared to competitors [1][2] - Giant Bio's stock price has seen significant volatility, with a drop of over 15% recently and reaching a new low of 40.6 HKD, reflecting investor concerns about its sales performance [1] - Citigroup's report indicates that the company's revenue growth is expected to be 16% year-on-year in the second half of the year, despite a projected decline of 10% on Tmall [2] Group 2 - Citigroup predicts that Giant Bio's sales will recover in the fiscal year 2026, with a high growth rate of 19% due to a low base and no negative customer feedback [2] - The target price for Giant Bio's stock has been adjusted from 69.4 HKD to 55.4 HKD based on a 20 times price-to-earnings ratio for the fiscal year 2026, while maintaining a "buy" rating [2] - The performance of KOL live broadcasts is noted to be declining, impacting the company's sales, with expectations of a 25% increase on Douyin and a 100% increase on JD, while offline sales are expected to grow by 10% [2]
港股异动 | 巨子生物(02367)续跌近3% 昨日重挫逾15% 花旗指其双11开局疲软